2018
DOI: 10.1016/j.contraception.2018.08.009
|View full text |Cite
|
Sign up to set email alerts
|

DMPA-SC: an emerging option to increase women's contraceptive choices

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 10 publications
(3 citation statements)
references
References 23 publications
0
3
0
Order By: Relevance
“…Within the group of DMPA injectables, women have three options: 1) DMPA-SC self-injection (SI), 2) DMPA-SC provider-administered (PA); or 3) DMPA-IM, which is not designed for self-administration. As a contraceptive self-care method [4], DMPA-SC has the potential to reduce barriers to contraceptive use, particularly in settings with limited health workforce and for populations for whom repeated facilitybased care-seeking is otherwise challenging or undesirable, including those facing stigma or who wish to use a contraceptive method covertly [5]. One feature that makes DMPA-SC SI unique among its DMPA alternatives is the exibility for users to inject themselves outside of the health facility setting.…”
Section: Introductionmentioning
confidence: 99%
“…Within the group of DMPA injectables, women have three options: 1) DMPA-SC self-injection (SI), 2) DMPA-SC provider-administered (PA); or 3) DMPA-IM, which is not designed for self-administration. As a contraceptive self-care method [4], DMPA-SC has the potential to reduce barriers to contraceptive use, particularly in settings with limited health workforce and for populations for whom repeated facilitybased care-seeking is otherwise challenging or undesirable, including those facing stigma or who wish to use a contraceptive method covertly [5]. One feature that makes DMPA-SC SI unique among its DMPA alternatives is the exibility for users to inject themselves outside of the health facility setting.…”
Section: Introductionmentioning
confidence: 99%
“…Subcutaneous depot medroxyprogesterone acetate (DMPA-SC) is a newly introduced injectable contraceptive, first approved in 2015 and now registered in over 33 countries [3] , [4] . Its design that combines the drug and needle in a prefilled system makes it simple to administer hence providing users with the option to self-inject as well as facilitating task-sharing to other cadres such as community health workers [3] , [5] . There is evidence of demonstrated high levels of acceptability and method satisfaction among DMPA-SC users [6] , [7] .…”
Section: Introductionmentioning
confidence: 99%
“…However, there are challenges in rolling out this new efficacious intervention, and major implementation problems have been encountered during scale-up [ 8 – 13 ]. One challenge is identifying the barriers that prevent effective implementation and strategies to mitigate these problems [ 14 ]. Furthermore, many of these interventions are described in the grey literature and are not published in peer-reviewed journals, of which systematic reviews have been conducted.…”
Section: Introductionmentioning
confidence: 99%